Merck Seeks Federal Circuit Review on Decision Regarding Mavenclad Patents

By Editorial Team

German pharmaceutical giant Merck has petitioned the Federal Circuit to reconsider its ruling that upheld the invalidation of claims in two patents related to the popular multiple sclerosis drug Mavenclad. Merck argues that the decision sets a precedent where inventors' own work could be used against them.

The patents in question are U.S. Patent No. 7,713,947 and U.S. Patent No. 8,377,903, both covering the use of cladribine in treating multiple sclerosis. The Federal Circuit's decision to uphold the invalidation of these patents has prompted Merck to seek a review of the ruling.

Merck is represented by law firms Husch Blackwell, Sterne Kessler, and WilmerHale in this matter. The companies involved in the case include EMD Serono Inc., Merck & Co. Inc., and Merck KGaA.

This legal battle involves significant implications for the pharmaceutical industry and intellectual property rights. Merck's move to challenge the Federal Circuit's decision underscores the company's commitment to protecting its intellectual property assets, particularly in the competitive landscape of the life sciences sector.

For more details on this case and its potential impact on the pharmaceutical industry, stay tuned for further updates.